Cambridge Investment Research Advisors
HZNP

Cambridge Investment Research Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,083
Closed -$1.05M – 3349
2023
Q3 		$1.05M Sell
9,083
-714
-7% -$76.7K ﹤0.01% 1542
2023
Q2 		$1.01M Sell
9,797
-3,609
-27% -$381K ﹤0.01% 1609
2023
Q1 		$1.46M Sell
13,406
-1,251
-9% -$138K 0.01% 1330
2022
Q4 		$1.67M Sell
14,657
-1,571
-10% -$130K 0.01% 1183
2022
Q3 		$1M Buy
16,228
+1,804
+13% +$126K 0.01% 1477
2022
Q2 		$1.15M Sell
14,424
-1,213
-8% -$115K 0.01% 1375
2022
Q1 		$1.65M Sell
15,637
-3,741
-19% -$365K 0.01% 1258
2021
Q4 		$2.09M Buy
19,378
+924
+5% +$101K 0.01% 1121
2021
Q3 		$2.02M Sell
18,454
-2,298
-11% -$239K 0.01% 1092
2021
Q2 		$1.94M Buy
+20,752
New +$1.91M 0.01% 1141
2021
Q1 		– Sell
-8,605
Closed -$629K – 3035
2020
Q4 		$629K Buy
8,605
+3,234
+60% +$240K ﹤0.01% 1614
2020
Q3 		$417K Buy
+5,371
New +$370K ﹤0.01% 1724
2020
Q2 		– Sell
-10,463
Closed -$310K – 2550
2020
Q1 		$310K Buy
+10,463
New +$354K ﹤0.01% 1663

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cambridge Investment Research Advisors's HZNP Position: Q4 2023 in Review

Cambridge Investment Research Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 9,083 shares — an estimated $1.05M sold.

Cambridge Investment Research Advisors first reported a position in HZNP in Q1 2020 and held it in 13 quarters. The position peaked at $2.09M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Cambridge Investment Research Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 9,083 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.05M.
  • Cambridge Investment Research Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 13 quarters.
  • Cambridge Investment Research Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.09M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.